PRX-102 successfully met the primary endpoint on kidney function in active control, non-inferiority study vs. agalsidase beta
Topline results demonstrated a favorable tolerability and immunogenicity profile for PRX-102
BLA resubmission planned for the second half of 2022
https://finance.yahoo.com/news/protalix-biotherapeutics-chiesi-global-rare-105000805.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.